{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:54:39Z","timestamp":1773424479463,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003960.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"reference-count":51,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003960.pub3","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T16:19:30Z","timestamp":1192033170000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Tegaserod for the treatment of irritable bowel syndrome and chronic constipation"],"prefix":"10.1002","author":[{"given":"Beti W","family":"Evans","sequence":"first","affiliation":[{"name":"University of Hertfordshire; School of Pharmacy; College Lane Campus Hatfield UK AL10 9AB"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy K","family":"Clark","sequence":"additional","affiliation":[{"name":"Keele University; Medicines Management; Department of Medicines Management Keele University Newcastle-under-Lyme Staffordshire UK ST5 5BG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Moore","sequence":"additional","affiliation":[{"name":"University of Birmingham; Aggressive Research Intelligence Facility; Aggressive Research Intelligence Facility Department of Public Health & Epidemiology University of Birmingham West Midlands UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Whorwell","sequence":"additional","affiliation":[{"name":"Wythenshawe Hospital; Medical Academic Department; First floor, Education and Research Centre Southmoor Road Manchester UK M23 9LT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"key":"10.1002\/14651858.CD003960.pub3-BIB0001|cit1","unstructured":"Novartis Pharmaceuticals Corporation East Hanover New Jersey Zelmac (tegaserod) Advisory Committee Briefing Document http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf 1 93"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1572-0241.2002.05692.x","article-title":"Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms","volume":"97","author":"Fidelholtz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0003|cit3","unstructured":"Rawls J Lefkowitz M Shi Y Zack A Dunger-Baldauf C Ruegg PC Gut 2000 A217"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0004|cit4","unstructured":"Hamling J Bang CJ Tarpila S Stewart W Rueegg PC Digestion 1998 735 (abstract B5324)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0005|cit5","unstructured":"Novartis Pharmaceuticals Corporation East Hanover New Jersey Zelmac (tegaserod) Advisory Committee Briefing Document http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf 1 93"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Johansen JF Tougas G Chey WD Novick JS Lembo A Fordham F Guella MP Nault B Tegaserod provides rapid and sustained relief of constipation, abdominal bloating\/distension, and abdominal discomfort\/pain in patients with chronic constipation Gastroenterology 2003 Abs 371 (A-47)","DOI":"10.1016\/S0016-5085(03)80234-2"},{"issue":"9","key":"10.1002\/14651858.CD003960.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1542-3565(04)00356-8","article-title":"Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial","volume":"2","author":"Johanson","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Wald A Johanson J Tougas G Chey W Novick J Lembo A Fordham F Guella M Nault B Safety and tolerability of tegaserod in patient treated for chronic constipation (CC): A 12 week, double-blind, placebo-controlled multicenter study performed in the Americas Gastroenterology 2003 Abs T1818 (A-573)","DOI":"10.1016\/S0016-5085(03)82902-5"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1572-0241.2005.40749.x","article-title":"Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study","volume":"100","author":"Kamm","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0011|cit11","unstructured":"Kellow JE Lee O Thongsawat S Zawawi M Yuen H Gwee K Tegaserod is an effective therapy for non-diarrhea irritable bowel syndrome in an Asian-Pacific population Gut 2002 A11 (abstract 035)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2036.2006.02705.x","article-title":"Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome","volume":"23","author":"Khoshoo","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0013|cit13","unstructured":"Lefkowitz MP Ruegg P Shi Y Dunger-Baldauf C Gastroenterology 1999 A1027 (abstract G4462)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0014|cit14","first-page":"1","article-title":"Zelmac (tegaserod) Advisory Committee Briefing Document","author":"Novartis Pharmaceuticals Corporation East","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0015|cit15","unstructured":"Whorwell P Muller-Lissner S Langaker KJ Wald A Pruitt R Ruegg P Gut 1999 A260 (abstract P0966)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0016|cit16","unstructured":"Krumholz S Tanghe J Schmitt C Heggland J Shi Y Ruegg PC Gut 1999 A260 (abs P0965)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0017|cit17","unstructured":"Lefkowitz M Shi Y Heggland J Dunger-Baldauf C Ruegg PC Tegaserod rapidly improves abdominal pain, bloating and bowel function in patients with C-IBS Gut 2000 A217 (abstract P833)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0018|cit18","unstructured":"Lefkowitz M Shi Y Schmitt C Krumholtz S Tanghe J Am J Gastroenterol 1999 2676 (abstract 396)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0019|cit19","first-page":"1","article-title":"Zelmac (tegaserod) Advisory Committee Briefing Document","author":"Novartis Pharmaceuticals Corporation East","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0020|cit20","unstructured":"Schmitt C Krumholz S Tanghe J Heggland J Shi Y Lefkowitz M Gut 1999 A258 (abstract P0960)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0021|cit21","first-page":"A175 (abs 1000)","article-title":"Tegaserod, a 5HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS)","volume":"116 (Suppl 2)","author":"Mueller-Lissner","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0023|cit23","first-page":"1","article-title":"Zelmac (tegaserod) Advisory Committee Briefing Document","author":"Novartis Pharmaceuticals Corporation East","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Lefkowitz M Ligozio G Glebas K Heggland JE Gastroenterology 2001 A22 (abstract 104)","DOI":"10.1016\/S0016-5085(08)80106-0"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD003960.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"A389","DOI":"10.1016\/S0016-5085(03)81972-8","article-title":"Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population","volume":"124","author":"Nyhlin","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003960.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00365520310006748","article-title":"A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patient with irritable bowel syndrome","volume":"39","author":"Nyhlin","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2036.2005.02577.x","article-title":"Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation","volume":"22","author":"Reilly","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/gut.2005.070789","article-title":"A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation","volume":"54","author":"Tack","year":"2005","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0030|cit30","unstructured":"Appel-Dingemanse S Rawls J Heggland J Campestrini J Sechaud R Gastroenterology 2000 Abstract 5340"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0032|cit31","unstructured":"Bardhan KD Forbes A Marsden CL A clinical investigation of the effects of tegaserod treatment regimen on the symptoms of IBS-C in tegaserod-responsive patients Gut 2003 Abs 053"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0031|cit32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2036.2004.02032.x","article-title":"The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain\/discomfort, bloating and constipation: a clinical study","volume":"20","author":"Bardhan","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","article-title":"Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1046\/j.1365-2036.2002.01347.x","article-title":"Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome","volume":"16","author":"Tougas","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD003960.pub3-BIB0035|cit35","first-page":"88","article-title":"[A randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome] [Chinese]","volume":"42","author":"Tegaserod Clinical Research Group","year":"2003","journal-title":"Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0036|cit36","unstructured":"Chey WD Pare P Viegas A Ligozio G Shetzline MA Tegaserod improves multiple symptoms in women with mixed\/alternating bowel habits as well as those with IBS-C Gastroenterology 2006 Abs 135 (A-26)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0037|cit37","unstructured":"Lin S Zhou L Xinguang L Ke M Wang H Cheng L Digestive Disease Week 2003 Abs S1017"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0038|cit38","unstructured":"Munoz VC Digestive Disease Week 2003 Abs T1804"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2001.21908","article-title":"Management of the irritable bowel syndrome","volume":"120","author":"Camilleri","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/bmj.310.6973.171","article-title":"Irritable bowel, irritable body, or irritable brain?","volume":"310","author":"Farthing","year":"1995","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199856010-00002","article-title":"New drugs in the management of the irritable bowel syndrome","volume":"56","author":"Farthing","year":"1998","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0042|cit42","unstructured":"FDA Public Health Advisory (March 30, 2007) www.fda.gov\/cder\/drug\/advisory\/tegaserod.htm [accessed 27.05.07]"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0043|cit43","unstructured":"FDA permits restricted use of Zelnorm for qualifying patients http:\/\/www.fda.gov\/bbs\/topcs\/NEWS\/2007\/NEW01673.html"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S0002-9343(99)00276-4","article-title":"Diagnostic criteria for the irritable bowel syndrome","volume":"107","author":"Hammer","year":"1999","journal-title":"Am J Med"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0045|cit45","first-page":"1","article-title":"British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome","volume":"47 (Suppl 2)","author":"Jones","year":"2000","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1572-0241.2002.05986.x","article-title":"Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects","volume":"97","author":"Morganroth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0047|cit47","unstructured":"Novartis Pharmaceuticals Corporation East Hanover New Jersey Zelmac (tegaserod) Advisory Committee Briefing Document http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b1a.pdf 1 93"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0048|cit48","unstructured":"Robinson A Lee V Thompson DG Irritable bowel syndrome diagnosed in primary care: how many patients fulfil Rome II criteria? Gut 2001 A45 (abstract 164)"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(02)09712-X","article-title":"Irritable bowel syndrome: a little understood organic bowel disease","volume":"360","author":"Talley","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00042737-199707000-00008","article-title":"Irritable bowel syndrome: the view from general practice","volume":"9","author":"Thompson","year":"1997","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD003960.pub3-BIB0051|cit51","first-page":"II69","article-title":"Design of treatment trials for functional gastrointestinal disorders","volume":"Suppl II","author":"Zanten","year":"1999","journal-title":"Gut"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003960.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:28:11Z","timestamp":1628544491000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003960.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2007,10,17]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003960.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,17]]}}}